Cipazoxapine is an atypical antipsychotic that has been studied for its potential therapeutic benefits in conditions such as schizophrenia and bipolar disorder. It acts as a dopamine and serotonin antagonist, and it has been shown to be effective in treating both positive and negative symptoms of schizophrenia. The synthesis of cipazoxapine involves a multi-step process that begins with the reaction of a substituted benzophenone with an appropriate amine. The resulting compound is then subjected to a series of reactions, including cyclization and oxidation, to yield the final product. The effects of cipazoxapine are primarily mediated through its interaction with dopamine and serotonin receptors in the brain. It has been shown to block dopamine receptors, which is believed to contribute to its antipsychotic effects. Additionally, cipazoxapine also blocks serotonin receptors, which may contribute to its mood-stabilizing effects. Cipazoxapine is being studied because it offers a potential alternative treatment for patients with schizophrenia and bipolar disorder who do not respond adequately to existing medications. The research on cipazoxapine has shown promising results in terms of its efficacy and safety. However, more research is needed to fully understand its long-term effects and its potential benefits and risks. '
cipazoxapine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 54359 |
| CHEMBL ID | 2105557 |
| SCHEMBL ID | 2110369 |
| MeSH ID | M0149151 |
| Synonym |
|---|
| cipazoxapine |
| L005140 |
| savoxepin |
| savoxepina [spanish] |
| savoxepine |
| 3-(cyclopentylmethyl)-2,3,4,5-tetrahydro-1h-dibenz(2,3:6,7)oxepino(4,5-d)azepine-7-carbonitrile |
| 13343j27ci , |
| savoxepina |
| 79262-46-7 |
| savoxepine [french] |
| savoxepin [inn] |
| unii-13343j27ci |
| savoxepinum [latin] |
| savoxepinum |
| CHEMBL2105557 |
| DTXSID20229594 |
| SCHEMBL2110369 |
| 18-(cyclopentylmethyl)-8-oxa-18-azatetracyclo[13.5.0.02,7.09,14]icosa-1(15),2(7),3,5,9,11,13-heptaene-4-carbonitrile |
| Q27251468 |
Cipazoxapine is a new tetracyclic dopamine antagonist which we tested to validate an animal model for neuroleptics.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cipazoxapine is a new tetracyclic dopamine antagonist which we tested to validate an animal model for neuroleptics. " | ( Neuroleptic profile of cipazoxapine (Savoxepine), a new tetracyclic dopamine antagonist: clinical validation of the hippocampus versus striatum ratio model of dopamine receptors in animals. A preliminary report. Bech, P; Butler, B, 1987) | 2.03 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " In vitro release studies have demonstrated that by varying the mean size of the nanoparticles and their drug loading, the release of the drug from the nanoparticles can be modulated to last from several hours to more than 30 days, thus allowing the preparation of an injectable extended-release dosage form." | ( In vitro extended-release properties of drug-loaded poly(DL-lactic acid) nanoparticles produced by a salting-out procedure. Allémann, E; Doelker, E; Gurny, R; Leroux, JC, 1993) | 0.29 |
| " An adequate test of the theory that preference for hippocampal dopamine D2 receptors with afford a good therapeutic ratio requires an alternative dosing regimen." | ( Savoxepine: striatal dopamine-D2 receptor occupancy in human volunteers measured using positron emission tomography (PET). Ametamey, S; Antonini, A; Beer, HF; Gerebtzoff, A; Gut, A; Leenders, KL; Locher, JT; Maître, L; Thomann, R; Weinreich, R, 1993) | 0.29 |
| " Using either a slower dose-titration or a high, single loading dose followed by a low maintenance dosing may have offered the possibility to obtain a good antipsychotic effect together with low incidence of EPS." | ( Savoxepine versus haloperidol. Reasons for a failed controlled clinical trial in patients with an acute episode of schizophrenia. Bischoff, S; Gerebtzoff, A; Möller, HJ; Volz, HP, 2002) | 0.31 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 6 (66.67) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (22.22%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (77.78%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||